Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus ESHAP followed by autologous stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma
2009-016026-13Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in classical Hodgkin lymphoma (cHL), sponsored by GELTAMO. Primary endpoints: Overall response rate after O-ESHAP and Complete response rate after O-ESHAP. Started Mar 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2009-016026-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016026-13.